pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial
Boehringer Ingelheim
Boehringer Ingelheim is a pharma organization headquartered in Ingelheim am Rhein, DE. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstruc
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
- Employees
- 46,699
- Programs
- 193
- Drugs
- 113
- Patents
- 25
BI 3011441
Phase 1 · small molecule · Solid Tumors, KRAS Mutation
BI 3011441 for Solid Tumors, KRAS Mutation is a Phase 1 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Internal code 1469-0002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Solid Tumors, KRAS Mutation
- Status
- completed
- Trials
- 1